OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Martin GutierrezVictor MorenoKimberley M HeinhuisAnthony J OlszanskiAnna SpreaficoMichael OngQuincy ChuRichard D CarvajalJose TrigoMaria Ochoa de OlzaMariano ProvencioFilip Yves De VosFilippo De BraudStephen LeongDeanne LathersRui WangPalani RavindranYan FengPraveen AanurIgnacio MeleroPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
In this study, BMS-986178 ± nivolumab and/or ipilimumab appeared to have a manageable safety profile, but no clear efficacy signal was observed above that expected for nivolumab and/or ipilimumab.
Keyphrases